1.Weighting Informativeness Features (incl calcs)

1 Number of trial sites in entire trial /

2 Multiple sites in a single country trial (Y/N)

3 Tertile of number of sites by domain by phase

4 Multiple countries (Y/N)

5 Number of countries with at least one site

6 Case report form pages-all trial

7 Case report form pages per variable (TBD)

8 Number of visits

9 Duration of trial

10 Tertile of primary duration

11 Duration of follow up (in months)

12 Number of procedures

13 Composite product of tertile of Primary Duration times tertile of Sample Size

14 tertile_of_sample_size by domain by phase

15 two-level binomial lowest tertile of sample size by domain by phase

16 # arms

17 includes analysis of real world data

18 phase-in-domain

19 # of endpoints

20 tertile of number of (co-)primary endpoints by domain by phase

21 Has an SAP

22 Prevalence estimate not discosed or funky

23 Effect estimate not disclosed or funky

24 Uses simulation for sample size

25 # of mentions of the word policy

26 Is a master protocol or a subset or derivative of a master protocol

27 Is part of a platform trial

28 Takes place in a hospital

29 Is an adaptive design

30 Uses model-informed drug development

31 Recency of protocol vs today's date

32 Recent dates in prevalence/burden citations

33 More than 1 drug in the intervention cocktail

34 Patient consortium or trial consortium prominently involved

35 Indicates intention or willingness to make changes at interim

2.Weighting Informativeness Features (no calcs)

1 Number of trial sites in entire trial /

2 Multiple sites in a single country trial (Y/N)

3 Multiple countries (Y/N)

4 Number of countries with at least one site

5 Case report form pages-all trial

6 Case report form pages per variable (TBD)

7 Number of visits

8 Duration of trial

9 Duration of follow up (in months)

10 Number of procedures

11 # arms

12 includes analysis of real world data

13 phase-in-domain

14 # of endpoints

15 Has an SAP

16 Prevalence estimate not discosed or funky

17 Effect estimate not disclosed or funky

18 Uses simulation for sample size

19 # of mentions of the word policy

20 Is a master protocol or a subset or derivative of a master protocol

21 Is part of a platform trial

22 Takes place in a hospital

23 Is an adaptive design

24 Uses model-informed drug development

25 Recency of protocol vs today's date

26 Recent dates in prevalence/burden citations

27 More than 1 drug in the intervention cocktail

28 Patient consortium or trial consortium prominently involved

29 Indicates intention or willingness to make changes at interim